DNA topoisomerases in cancer chemotherapy: basic and applied aspects. 2001

F Cortés, and N Pastor
Department of Cellular Biology, Faculty of Biology, University of Seville, Spain.

These conserved nuclear enzymes catalyse a variety of interconversions of DNA which take place between topological isoforms of the molecule, through transient cleavage, strand passing and re-ligation. In this context the DNA topoisomerases have been generally considered as good candidates to play a role in the enzymatic repair processes going on in the cell after DNA damage inflicted by either physical or chemical agents. It has been suggested that this role could be direct, with the actual participation of topoisomerases in the molecular mechanism of lesion repair, as for example in the excision of base damage or DNA strand break repair. Alternatively, it could be indirectly responsible for the preparative steps in the relaxation of chromatin in order to allow repair enzymes to gain access to damaged DNA.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014466 Ultraviolet Rays That portion of the electromagnetic spectrum immediately below the visible range and extending into the x-ray frequencies. The longer wavelengths (near-UV or biotic or vital rays) are necessary for the endogenous synthesis of vitamin D and are also called antirachitic rays; the shorter, ionizing wavelengths (far-UV or abiotic or extravital rays) are viricidal, bactericidal, mutagenic, and carcinogenic and are used as disinfectants. Actinic Rays,Black Light, Ultraviolet,UV Light,UV Radiation,Ultra-Violet Rays,Ultraviolet Light,Ultraviolet Radiation,Actinic Ray,Light, UV,Light, Ultraviolet,Radiation, UV,Radiation, Ultraviolet,Ray, Actinic,Ray, Ultra-Violet,Ray, Ultraviolet,Ultra Violet Rays,Ultra-Violet Ray,Ultraviolet Black Light,Ultraviolet Black Lights,Ultraviolet Radiations,Ultraviolet Ray
D059003 Topoisomerase Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASES. DNA Topoisomerase Inhibitor,Topoisomerase Inhibitor,DNA Topoisomerase Inhibitors,Inhibitor, DNA Topoisomerase,Inhibitor, Topoisomerase,Inhibitors, DNA Topoisomerase,Inhibitors, Topoisomerase,Topoisomerase Inhibitor, DNA,Topoisomerase Inhibitors, DNA
D026942 DNA Topoisomerases Enzymes that regulate the topology of DNA by actions such as breaking, relaxing, passing, and rejoining strands of DNA in cells. These enzymes are important components of the DNA replication system. They are classified by their substrate specificities. DNA TOPOISOMERASE I enzymes act on a single strand of DNA. DNA TOPOISOMERASE II enzymes act on double strands of DNA. Topoisomerases, DNA

Related Publications

F Cortés, and N Pastor
January 1991, Cancer cells (Cold Spring Harbor, N.Y. : 1989),
F Cortés, and N Pastor
January 1986, Advances in protein chemistry,
F Cortés, and N Pastor
January 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
F Cortés, and N Pastor
October 2002, Current opinion in investigational drugs (London, England : 2000),
F Cortés, and N Pastor
June 1988, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
F Cortés, and N Pastor
January 1990, Medical oncology and tumor pharmacotherapy,
F Cortés, and N Pastor
April 1988, British medical journal (Clinical research ed.),
F Cortés, and N Pastor
October 1987, Anti-cancer drug design,
F Cortés, and N Pastor
August 1974, Rinsho byori. The Japanese journal of clinical pathology,
F Cortés, and N Pastor
January 1987, NCI monographs : a publication of the National Cancer Institute,
Copied contents to your clipboard!